ENPP2 and idiopathic pulmonary fibrosis: Currently, there are several mechanisms being tested in the clinic for IPF patients, including but not limited to the CTGF antibody Pamrevlumab, the Autotaxin inhibitor GLPG-1690, and recombinant Pentraxin 2 (PRM-151).